Here is a worldwide view of 2021's Top-10 best-selling drugs. The cumulative sales revenue of these 10 drugs in 2021 will reach 109.75 billion U.S. dollars.

Humira (adalimumab) continues to dominate the biopharmaceutical world with expected sales close to $20 billion. From its launch in 2003 to the end of June 2020, Humira has achieved cumulative sales of $165.8 billion. Effective this year, the product has taken over the crown-position of the drug industry's most commercially-successful launch from Lipitor (atorvastatin). Lipitor is a cholesterol-lowering drug with a total sales revenue of $160 billion over 23 years since launch.

There are 4 anticancer drugs on the list. Keytruda (pembrolizumab), a checkpoint inhibitor for multiple cancers, will reach sales of $16.8 billion in 2021, and is expected to surpass Humira's sales in 2024.

And while the COVID-19 vaccines are a monumental achievement for the industry, none are not expected to enter the top ten in 2021. Among the vaccines that are leading the way in commercialization, Pfizer/BioNTech's BNT162b2 and Moderna's mRNA-1273 are expected to have sales of $2.5 billion and $2 billion in 2021, respectively.

The list was published by Nature with consensus forecasts provided by EvaluatePharma.